Biocryst Pharmaceuticals (BCRX) Interest Expenses (2011 - 2026)

Biocryst Pharmaceuticals' Interest Expenses history runs 16 years deep, the most recent figure standing at $71.0 million for Q1 2026.

• Quarterly Interest Expenses rose 202.25% year-over-year to $71.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.0 million (down 53.08% YoY) and the FY2025 annual result came in at $380.5 million, down 15.2% from the prior year.
• Interest Expenses was $71.0 million for Q1 2026 at Biocryst Pharmaceuticals, up from $14.1 million in the prior quarter.
• Across five years, Interest Expenses topped out at $90.9 million in Q4 2023 and bottomed at $14.1 million in Q4 2025.
• A 5-year average of $34.4 million and a median of $24.8 million in 2024 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses soared 243.52% — and 2025, when it sank 81.94%.
• Biocryst Pharmaceuticals' Interest Expenses stood at $26.5 million in 2022, then surged by 243.52% to $90.9 million in 2023, then fell by 13.88% to $78.3 million in 2024, then sank by 81.94% to $14.1 million in 2025, then soared by 402.37% to $71.0 million in 2026.
• Business Quant data shows BCRX's Interest Expenses at $71.0 million in Q1 2026, $14.1 million in Q4 2025, and $29.0 million in Q3 2025.